Leal T, et al. Identifying resistance to immune checkpoint inhibitors by screening for PD-L1 and MHC I expression on CTCS in pts with NSCLC. IASLC 2018; abstract P3.04-08.
Tucatinib verlengt mediane overleving met 5,5 maand in finale analyse HER2CLIMB-studie
mrt 2022 | Borstkanker